SCHEMBL876320

SCHEMBL876320

CC(F)(F)Oc1cccn2c(=O)cc(Cl)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
MPI P34949 1/20 0.38
MAPT P10636 2/20 0.33
GUCY1B2 O75343 1/20 0.32
GUCY1A2 P33402 1/20 0.32
GUCY1A1 Q02108 1/20 0.32
GUCY1B1 Q02153 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2A Q12879 1/20 0.32
GRM5 P41594 1/20 0.32
ATP4A P20648 1/20 0.32
ATP4B P51164 1/20 0.32
POLB P06746 1/20 0.32
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875453 0.84 LMNA (0.44) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL2149880 0.82 LMNA (0.42) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL876018 0.80 PIK3CD (0.37) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL875143 0.77 KDM4E (0.40) KDM4EMAPTGUCY1B2GUCY1A2GUCY1A1
SCHEMBL876113 0.74 KDM4E (0.52) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL875530 0.73 MAPT (0.37) LMNAKDM4EALDH1A1MAPT
SCHEMBL8171222 0.71 KDM4E (0.42) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL3715566 0.71 KDM4E (0.65) LMNAKDM4EALDH1A1GLAGAA
SCHEMBL876309 0.69 KCNQ2 (0.36) KDM4EMAPTGUCY1B2GUCY1A2GUCY1A1
SCHEMBL876238 0.69 MCHR1 (0.39) GUCY1B2GUCY1A2GUCY1A1GUCY1B1ATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619202-A1 PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES Pfizer Inc (US) 2013-07-31 EP disclosed
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases PFIZER INC. (US) 2013-07-18 US disclosed
WO-2012038850-A1 PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES PFIZER INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184294-A1 Pyrimidones for Treatment of Potassium Channel Related Diseases KCNQ5, KCNQ1, KCNQ3 LMNA 2748/4885KDM4E 2185/4885ALDH1A1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.